Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Total Liabilities (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Total Liabilities for 4 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 35.9% to $10.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 35.9% decrease, with the full-year FY2025 number at $10.5 million, down 35.9% from a year prior.
  • Total Liabilities was $10.5 million for Q4 2025 at Spruce Biosciences, up from $9.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $31.1 million in Q1 2023 to a low of $8.6 million in Q2 2025.
  • A 4-year average of $18.3 million and a median of $16.4 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 111.03% in 2023, then crashed 51.22% in 2024.
  • Spruce Biosciences' Total Liabilities stood at $17.2 million in 2022, then surged by 59.87% to $27.4 million in 2023, then crashed by 40.27% to $16.4 million in 2024, then plummeted by 35.9% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Total Liabilities are $10.5 million (Q4 2025), $9.9 million (Q3 2025), and $8.6 million (Q2 2025).